The analysis also found the therapy has a manageable safety profile. A new meta-analysis of chimeric antigen receptor (CAR) T-cell therapy in patients with multiple myeloma (MM) suggests the treatment ...
That past goes back nearly 76 years to 1947, when Enzo Ferrari built the first Prancing Horse to wear the enamel Cavallino emblem bearing his name. To look at a Ferrari from the first decade of the ...
Leland Metheny, MD, is lead investigator for the Phase 1 BAFF CAR T clinical trial, which is evaluating the safety and effectiveness of a novel approach to chimeric antigen receptor (CAR) T-cell ...
The U.S. FDA’s Oncology Drugs Advisory Committee, in two separate sessions, took up the matters of Carvykti (ciltacabtagene autoleucel) from Johnson & Johnson and the Bristol Myers Squibb Co. product ...
Patients with relapsed/refractory multiple myeloma (r/r MM) treated with Carsgen Therapeutics Holdings Ltd.’s CAR T therapy, zevorcabtagene autoleucel (zevor-cel, CT-053), have shown durable responses ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback